The primary goal of this integrated, multi-interventional curriculum of both live and online activities is to provide an educational initiative for primary care physicians, physician assistants (PAs) and nurse practitioners (NPs) on the advantages and disadvantages of prandial insulin, the clinical profiles of GPL-1 receptor agonists, and the benefits of combining GLP-1 receptor agonists with basal insulin.
This activity is part of the ConnectED Learning: Diabetes curriculum. In this Expert Perspective, Dr. Richard Pratley outlines the main facets of utilizing oral combination therapy to intensify treatment in order to achieve HbA1c goals while minimizing side effects and cardiovascular risk.
For a growing number of patients with diabetes, concentrated insulins may be the ideal agents in order to best address challenges of insulin resistance while improving health outcomes. However, the unique properties of these agents mean that each form of concentrated insulin serves a specific function in the overall management of diabetes. It is critical that clinicians are comfortable distinguishing concentrated insulins and selecting ideal patients for treatment as an intimate knowledge of these agents will allow clinicians to optimize treatment and reduce risks. In this interactive case-based roundtable discussion, expert faculty will guide learners through overcoming barriers associated with insulin use, distinguishing among approved concentrated insulin products, identifying patients who would benefit from concentrated insulin therapy, and employing best practices in management in order to minimize risks such as hypoglycemia.
This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes
This case outlines nuances of intensifying therapy with oral antidiabetic agents based on patient and disease characteristics
This activity is part of the ConnectED Learning: Diabetes curriculum. This case will highlight best practices of intensifying therapy with oral combination regimens in individuals with T2DM.
Follow the complex case of a 55-year-old patient who presents with long-standing, uncontrolled type 2 diabetes requiring individualized care. Filled with common scenarios relevant to primary care, this case distinguishes nuances in management based on patient- and disease-specific factors while enhancing your knowledge on the myriad diabetes therapies available today.
The landscape of diabetes treatment has shifted from a “one-size-fits-all” paradigm to one involving individualized care accounting for patient factors, preferences, and comorbidities. Participate in this 90-minute expert panel discussion to learn about the safety and efficacy of newer non-insulin therapies for type 2 diabetes, such as SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and their combinations. Faculty experts will answer crucial participant questions, explain considerations for selecting therapies based on guideline recommendations, and distill the latest clinical data for non-insulin T2DM management into concepts relevant to primary care.
New therapeutic options have emerged in the type 2 diabetes (T2DM) management paradigm that improve hyperglycemic control while decreasing cardiovascular risk. Watch this expert-led 90-minute panel discussion to learn about exciting new research on cardiovascular outcomes studies of antidiabetic agents and the resultant practical applications for patient care. Participants in this program will also receive expert advice on using ADA and AACE/ACE guidelines appropriately as well as other strategic insights to improve care for their patients with T2DM and cardiovascular risk.
This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.
Dr. de la Cruz-Muñoz, an expert in laparoendoscopic and bariatric surgery, will review evidence regarding the treatment of obese patients with uncontrolled type 2 diabetes with bariatric surgery.